Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.

Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE, List AF, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):711-5. doi: 10.1016/j.clml.2013.07.007. Epub 2013 Sep 17.

PMID:
24054159
2.

Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.

Harel S, Cherait A, Berthon C, Willekens C, Park S, Rigal M, Brechignac S, Thépot S, Quesnel B, Gardin C, Adès L, Fenaux P, Braun T.

Leuk Res. 2015 May;39(5):501-4. doi: 10.1016/j.leukres.2015.02.004. Epub 2015 Feb 16.

PMID:
25735917
3.

Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.

Duong VH, Bhatnagar B, Zandberg DP, Vannorsdall EJ, Tidwell ML, Chen Q, Baer MR.

Leuk Lymphoma. 2015 Jun;56(6):1718-22. doi: 10.3109/10428194.2014.966708. Epub 2014 Nov 3.

PMID:
25263320
4.

Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.

Zeidan AM, Al Ali NH, Padron E, Lancet J, List A, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):705-10. doi: 10.1016/j.clml.2015.08.083. Epub 2015 Sep 2.

PMID:
26440749
5.

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.

Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW.

J Clin Oncol. 2011 May 20;29(15):1987-96. doi: 10.1200/JCO.2010.30.9245. Epub 2011 Apr 11.

PMID:
21483003
6.

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.

Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP.

Cancer. 2007 Jan 15;109(2):265-73.

7.

Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome.

Lee JH, Choi Y, Kim SD, Kim DY, Lee JH, Lee KH, Lee SM, Lee WS, Joo YD.

Eur J Haematol. 2015 Jun;94(6):546-53. doi: 10.1111/ejh.12469. Epub 2015 Jan 7.

PMID:
25315896
8.

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.

Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias..

Cancer. 2010 Mar 15;116(6):1485-94. doi: 10.1002/cncr.24894.

9.

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.

Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H.

Cancer. 2010 Aug 15;116(16):3830-4. doi: 10.1002/cncr.25247.

10.

[Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].

Klepfish A, Silbershatz I, Lugassy G, Shimoni A, Mittelman M.

Harefuah. 2013 Oct;152(10):591-4, 624. Hebrew.

PMID:
24450031
11.

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F, Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat C, Kiladjian JJ, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM)..

Blood. 2010 Nov 11;116(19):3735-42. doi: 10.1182/blood-2010-03-274811. Epub 2010 Jul 27.

12.

Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.

Xie M, Jiang Q, Xie Y.

Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):22-8. doi: 10.1016/j.clml.2014.04.010. Epub 2014 Jun 12. Review.

PMID:
25042977
13.

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.

van der Helm LH, Alhan C, Wijermans PW, van Marwijk Kooy M, Schaafsma R, Biemond BJ, Beeker A, Hoogendoorn M, van Rees BP, de Weerdt O, Wegman J, Libourel WJ, Luykx-de Bakker SA, Minnema MC, Brouwer RE, Croon-de Boer F, Eefting M, Jie KS, van de Loosdrecht AA, Koedam J, Veeger NJ, Vellenga E, Huls G.

Br J Haematol. 2011 Dec;155(5):599-606. doi: 10.1111/j.1365-2141.2011.08893.x. Epub 2011 Oct 8.

PMID:
21981697
14.

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.

Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS.

Cancer. 2015 Mar 15;121(6):876-82. doi: 10.1002/cncr.29145. Epub 2014 Nov 19.

15.

Therapy with azanucleosides for myelodysplastic syndromes.

Quintás-Cardama A, Santos FP, Garcia-Manero G.

Nat Rev Clin Oncol. 2010 Aug;7(8):433-44. doi: 10.1038/nrclinonc.2010.87. Epub 2010 Jun 15. Review.

PMID:
20551943
16.

Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.

Kim DY, Lee JH, Lee JH, Lee KH, Kim YK, Ahn JS, Kim HJ, Kim I, Yoon SS, Park S, Bae SH, Bang SM, Lee HG, Shin HJ, Lee JH, Min YH, Won JH, Mun YC, Oh D; Korean Society of Hematology AML/MDS Working Party..

Ann Hematol. 2010 Jan;89(1):15-23. doi: 10.1007/s00277-009-0771-1. Epub 2009 Jun 19.

PMID:
19543727
17.

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.

Santini V, Prebet T, Fenaux P, Gattermann N, Nilsson L, Pfeilstöcker M, Vyas P, List AF.

Leuk Res. 2014 Dec;38(12):1381-91. doi: 10.1016/j.leukres.2014.09.008. Epub 2014 Sep 22. Review.

18.
19.

Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.

Li X, Chang C, He Q, Xu F, Zhang Q, Wu L, Su J, Zhang X, Zhou L, Wu D, Song L, Zhang Z.

Leuk Res. 2013 Nov;37(11):1516-21. doi: 10.1016/j.leukres.2013.09.006. Epub 2013 Sep 18.

PMID:
24084368
20.

Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.

Ozbalak M, Cetiner M, Bekoz H, Atesoglu EB, Ar C, Salihoglu A, Tuzuner N, Ferhanoglu B.

Hematol Oncol. 2012 Jun;30(2):76-81. doi: 10.1002/hon.986. Epub 2011 Mar 8.

PMID:
21387357

Supplemental Content

Support Center